natgillin/translations-raw huggingface dataset:
Thus, the first aspect of the present invention is a process for producing a food based on leavened dough, leavened puff pastry dough or puff pastry dough, comprising at least the following steps: 
HR P20180896 T1 PATENTNI ZAHTJEVI Postupak za proizvodnju prehrambenog proizvoda na bazi dizanog lisnatog tijesta ili lisnatog tijesta, koji sadržava slijedeće korake:
Desirable materials and thickness will be apparent to the skilled artisan. 
Poželjni materijali i debljine biti će očite iskusnom stručnjaku.
The suction cups present on the movable head are set side by side and mutually aligned, so that two lateral suction cups and a central suction cups can be identified. 
Usisne čašice koje se nalaze na pokretnoj glavi postavljene su jedna kraj druge i međusobno su poravnane, tako da dvije bočne usisne čašice i središnja usisna čašica mogu biti istovjetne.
A method for pretreating biomasses to allow their subsequent conversion to biofuel, characterized in that it comprises the following steps: 
PATENTNI ZAHTJEVI Metoda za prethodno tretiranje biomasa da bi se dozvolila njihova nadolazeća konverzija u biogorivo, naznačena time da sadrži sljedeće korake:
The method according to claim 1 for the prevention or the treatment of urogenital atrophy due to estrogen deficiency in women who are carrier of genetic mutations BRCA1 or BRCA2. The method according to claim 1 for the prevention or the treatment of urogenital atrophy due to estrogen deficiency in women who suffer or have suffered from an estrogen-dependent tumor selected from breast cancer, endometrial cancer, atypical endometrial hyperplasia, preneoplasic lesions, estrogen-dependent melanoma, estrogen-dependent ovarian cancer, estrogen-dependent haptic tumor, or myomas. 
Upotreba estriola u skladu s patentnim zahtjevom 1 u sprječavanju ili liječenju urogenitalne atrofije zbog nedostatka estrogena kod žena koje boluju od ili su bolovale od raka dojke, raka endometrija, atipične hiperplazije endometrija, preneoplasičnih lezija, melanoma ovisnog o estrogenu, raka jajnika ovisnog o estrogenu, tumora jetre ovisnog o estrogenu, ili od mioma; gdje navedene žene se liječe najmanje jednim lijekom koji inhibira proizvodnju ili ometa djelovanje estrogena u organizmu, ili gdje su navedene žene obavile uklanjanje jajnika.
A method of making a genetically modified mouse, comprising modifying the genome of a mouse by replacing a mouse genomic fragment coding for a mature mouse IL-15 polypeptide at the endogenous mouse IL-15 locus with a human genomic segment coding for a mature human IL-15 polypeptide wherein the human IL-15 exons in said human genomic segment consist of human IL-15 protein-coding exons 3, 4, 5 and 6, to form a humanized IL-15 gene, wherein the IL-15 exons are numbered with the first coding exon as exon 1, and wherein the humanized IL-15 gene is under control of all endogenous mouse IL-15 upstream regulatory elements at the endogenous mouse IL-15 locus. 
modificiranju genoma glodavca zamjenom fragmenta glodavačkog genoma koji kodira zreli glodavački polipeptid IL-15 na lokusu endogenog glodavačkog IL-15 genomskim fragmentom gena za ljudski IL-15 koji kodira zreli ljudski IL-15 polipeptid, kako bi se dobilo gen za humanizirani IL-15, gdje gen za humanizirani IL-15 sadrži sve egzone koji ne kodiraju protein iz glodavačkog IL-15 i regulacijska područja uzvodno od prvog egzona koji kodira protein iz gena za glodavački IL-15, a eksprimiranje gena za humanizirani IL-15 je pod kontrolom navedenih regulacijskih područja, i gdje gen za humanizirani IL-15 dovodi eksprimiranja proteina IL-15 koji kada je zreo je posve ljudski.
The composition of claim 1, wherein in the dihydroazole compound of formula (I): is oxygen; and 
Veterinarski ili agrikulturni sastav prema zahtjevu 1, naznačen time, da u spoju dihidroazola formule (I):
A solution of Compound 9.4B (2.0 g, 8.19 mmol) in phenyl ether (25 mL) was heated at reflux (250˜260° C.) under nitrogen for 2 hours. 
Otopina Spoja 9.4B (2.0 g, 8.19 mmol) u fenil eteru (25 ml) je zagrijavana uz refluks (250-260 C) uz dušik tijekom 2 sata.
An injectable insulin formulation for use in the treatment of a diabetic individual comprising injecting an effective amount of the injectable insulin formulation, wherein the injectable insulin formulation comprises insulin and an effective amount of a dissolution agent and a zinc chelator to enhance uptake and transport of the insulin through epithelial cells as compared to insulin in combination with a zinc chelator and HCI as defined by claim 1. 
Formulacija inzulina koja je namijenjena za davanje injekcijom prema bilo kojim prethodnim zahtjevima koja sadrži inzulin i učinkovitu količinu sredstva za otapanje i kelatora cinka za upotrebu u poboljšanju preuzimanja i transporta inzulina kroz epitelne stanice, u usporedbi s inzulinom u kombinaciji s navedenim kelatorom cinka i HCl, za liječenje pojedinca koji ima dijabetes.
heating the solution resulting from step (i) to a temperature of about 50 to 100°C in about 0.15 to 30 minutes; 
(1i) zagrijavanje otopine dobivene u koraku (1) do temperature od 50 do 100%C kroz 0.15 do 30 minuta;
the reaction of a compound of the formula (25): wherein PG is a protecting group, with a compound of the formula (22) as defined above under reductive amination conditions; 
(25) naznačen time da je PG zaštitna skupina, sa spojem formule (22) prema gornjoj definiciji, pod uvjetima aminacije, i nakon toga uklanjanje zaštitne skupine PG.
The methods, uses of oligonucleotides or oligonucleotide compositions and kits disclosed herein are preferably used and applicable for diagnosis, classification and/or prognosis of adverse events for patients or individuals, whereby these adverse events belong to at least one of the following categories: 
Uporaba postupka prema zahtjevima 1-3 za otkriće markera metilacije, pri čemu je marker indikativan za nuspojave kod pacijenata ili pojedinaca, gdje navedene nuspojave pripadaju u najmanje jednu od sljedećih kategorija neželjene interakcije s lijekovima; bolesti raka; stanični proliferacijski poremećaji; karcinom debelog crijeva; karcinom jetre;
wherein R2, R3 and R4 are as defined for formula (I) and X is a leaving group, or 
Ra gdje R3 i Ra su definirani kao za formulu (1), a X je izlazna skupina, te dalje izborno:
Figures 16 and 17 show dynamic light scattering spectra for IL-2 microaggregates. 
Slike 16 i 17 pokazuju spektar dinamičkog raspršenja svijetla za mikroagregate IL-2.
determining whether said level is above or below a value of 6.5 µg/ml, wherein a value below 6.5 µg/ml is indicative of Alzheimer's disease. 
određivanje da li je navedena razina iznad ili ispod vrijednosti od 6.5 ug/ml, pri čemu je vrijednost ispod 6.5 ug/ml indikativna za Alzheimerovu bolest.
A compound represented by the following formula, a salt thereof or a hydrate of the foregoing: wherein R1 represents a 3- to 10-membered non-aromatic heterocyclic group representing 
PATENTNI ZAHTJEVI 1. Spoj koji je prikazan sa slijedećom formulom, njegova sol ili bidrat navedenog:
CN103102237, European Patent Application Publication No. 
Datum podnošenja europske prijave patenta:
The most proximal component of the matrix provides the corneocytes of the dorsal nail surface. 
Najbliža komponenta matriksa daje korneocite dorzalne površine nokta.
In order to produce bags for the bread-baking sector, the weight of the paper layer 11 is increased to 50-55 grams per square meter if it is necessary to carry 4 to 5 kilograms of food. 
Da bi se proizvele vrećice za područje pečenja kruha, tožinu papirnatog sloja 11 poveća se na 50-55 grama po kvadratnom metru ako se mora nositi 4 do 5 kilograma hrane.
The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-4, wherein the binding is binding to a conformational or discontinuous epitope on human GDF-15. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno bilo kojem od patentnih zahtjeva 1-4, naznačeno time, da antitijelo ili njegov dio koji se veže za antigen je antitijelo ili njegov dio koji se veže za antigen sukladno zahtjevu 1 1), i gdje je vezanje vezivo na konformacijski ili diskontinuirani epitop na humanom GDF-15.
and finally with addition of morpholine to give the compound of the formula (IIIa). 
CH,SO- 1... i konačno uz dodavanje morfolina da se dobije spoj s formulom (1Ila).
A compound of Formula I, 
Spoj Formule I, I
A substituted morpholine or thiomorpholine derivative ot the general formula I wherein 
Supstituirani derivat morfolina ili tiomorfolina opće formule I R2
additional amino acids Met-Asp-Pro at the N-terminal end of the fusion protein sequence wherein the heterologous fusion partner protein derived from protein D, (b), is fused to the N-terminus of PRAME 
(c) dodatne aminokiseline Met-Asp-Pro na N-terminalnom kraju slijeda fuzijskog proteina gdje je heterologni proteinski partner u fuziji izveden iz proteina D, (b), fuzioniran s N-krajem PRAME.
A selective production of a C5S2$ clinker, the stabilization of C5S2$ at elevated temperatures, the potentially increased formation rate of a C2S, mixed crystals of the dicalcium silicate and the formation of at least one melt phase in the clinker and the use of the ternesite clinker as an additive in combination with reactive, aluminum-rich systems for the purpose of increasing the early strength of binders has not previously been described. 
Postupak sukladno barem jednom od zahtjeva 1 do 7, naznačen time što spojevi za sirove obroke, sadržaj agensa za ispravljanje, uvjeti sagorijevanja i regulacija procesa temperiranja odabrani su na takav način da CsS2$ i umjesto f- C28, reaktivne modifikacije C2S, na primjer a-modifikacije, proizvedeni su u povećanom opsegu.
formula (II) (stem-loop sequence with stem bordering elements): 
peteljka2 formula (II) (peteljka-omča sekvenca sa graničnim elementima peteljke):
The humanized anti-a2 integrin antibody of claim 1, wherein the antibody inhibits binding of a2 or a2B1 integrin to an a2B1 integrin ligand. 
Humanizirano anti-a2 integrin protutijelo prema zahtjevu 1, gdje protutijelo inhibira vezanje a2 ili a2B1 integrina za a2B1 integrin ligand.
arranging an assembly to be adjacent a decoking drum, said assembly comprising: a coke cutting tool (10) configured to receive a cutting fluid from a high pressure fluid source; and 
alat za rezanje koksa (10), konfiguriran za primanje reznog fluida iz izvora fluida pod visokim tlakom; i uređaj (200) za pomicanje navedenog alata za rezanje koksa (10) u bubnju za dekoksiranje, gdje navedeni uređaj (200) sadrži:
The monoclonal antibody for the use according to claim 1, wherein said antibody or antigen-binding portion possesses at least one of the following properties: inhibits glucocorticoid overriding (GCO) activity inhibits proliferation of cancer cells or fibroblasts 
Monoklonalno protutijelo ili njegov dio koji se veže na antigen prema zahtjevu 1, naznačen/o time, da spomenuto protutijelo ili njegov dio koji se veže na antigen, posjeduje najmanje jedno od sljedećih svojstava: a) inhibira preklapajuće djelovanje glukokortikoida (GCO) b) inhibira proliferaciju stanica raka ili fibroblasta
Pharmaceutical composition according to the preceding claim, comprising a mixture of at least 2 compounds according to formulae II, III, IV and/or V, and/or salts thereof. 
Farmaceutski pripravak u skladu s prethodnim patentnim zahtjevom, naznačen time što sadrži smjesu najmanje 2 spoja formula II, IIL, IV i/ili V, i/ili njihovih soli.
Preferably said tumor diseases are solid tumors, preferably epithelial tumors, such as prostate carcinoma; mammary carcinoma; pancreatic carcinoma; lung carcinoma; gastrointestinal tract carcinoma, such as colon carcinoma; kidney cancer; thyroid carcinoma; uterine carcinoma; adrenal carcinoma. According to another disclosure, said epithelial tumor is prostate carcinoma. In another preferred embodiment of the invention, the tumor diseases are prostate cancer with mutated or truncated Androgen Receptors. 
Spoj, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 7 ili 8, naznačen time što su navedene tumorske bolesti čvrsti tumori, po mogućnosti tumori epitela, poželjnije gdje su tumori epitela karcinom prostate; karcinom dojke; karcinom gušterače; karcinom pluća; karcinom gastrointestinalnog sustava, poput karcinoma debelog crijeva; rak bubrega; karcinom štitnjače; karcinom maternice; ili karcinom nadbubrežne žlijezde.
Y represents an oxygen atom; Z represent an oxygen atom or a sulfur atom; wherein, “substituent group a” represents a chemical group selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a C1-C6 alkylthio group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group, a nitro group, a cyano group, a phenyl group, and a methylenedioxy group; and 
je grupa odabrana iz grupe koja sadrži C1-C6 alkilnu grupu; C1-C6 haloalkilnu grupu; i piridilnu grupu; i "a grupa supstituenata" predstavlja grupu odabranu iz grupe koja se sastoji od: atoma halogena; C1-C6 alkilne grupe; C2-C6 alkenilne grupe; C2-C6 alkinilne grupe; C1-C6 haloalkilne grupe; C1-C6 alkoksi grupe; C1-C6 haloalkoksi grupe; C1-C6 alkiltio grupe; C1-C6 alkilsulfinilne grupe; C1-C6 alkilsulfonilne grupe; nitro grupe; cijano grupe; fenilne grupe; i metilendioksi grupe.
De novo papilla comprising a cell aggregate of mammalian dermal hair papilla fibroblasts (DPF), the cell aggregate exhibiting the shape and the size of a physiological dermal papilla (DP) of a hair follicle after isolation and being coated with extracellular matrix proteins, preferably collagen IV, fibronectin and/or laminin, wherein the de novo papilla is produced by a method comprising the steps of: 
Postupak prema zahtjevu 1, naznačen time da je barem jednu drugu staničnu populaciju moguće izvesti i/ili je izvedena iz folikula kose sisavaca, koja je odabrana iz skupine fibroblasta ovojnice vezivnog tkiva, keratinocita i/ili melanocita. Postupak prema zahtjevu 1 ili 2, naznačen time da je de novo papila iz koraka (a) prevučena sa izvanstaničnim matričnim proteinima, poželjno kolagenom IV, fibronektinom i/ili lamininom.
wherein the chimeric molecule lacks contiguous amino acid residues 1-273 and 285-364 as defined by reference to SEQ NO: 1, and wherein contacting the chimeric molecule to the cell inhibits the growth of the cell. The method of claim 11, wherein the ligand is an antibody or fragment thereof which has antigen recognition capability. 
(b) mutiranim PE iz bilo kojeg od zahtjeva 1 do 5, naznačena time da ta kimerička molekula ne sadržava ostatke 1 do 273 1 285 do 364 sekvencije SEQ ID NO: I. Kimerička molekula iz zahtjeva 9, koja je nadalje naznačena time da je (a) neko antitijelo ili fragment antitijela koji zadržava svojstvo prepoznavanja antigena.
The pharmaceutical composition for use according to claim 1, wherein the pharmaceutical composition is associated with polymer beads or polymer wafers impregnated with the BMP-4 protein preparation. 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je farmaceutski pripravak povezan s polimernim zrnima ili polimernim hostijama impregniranim preparatom proteina BMP-4.
at least one aperture (34, 38) through which the reinstatement materials may be expelled for delivery to a work side; wherein the aggregate materials and stabilising agent are preloaded into discreet capsules (81-84) which are inserted into the torpedo. 
- najmanje jedan otvor (34, 38) kroz koji se mogu izbaciti materijali za rekonstrukciju radi isporuke na radnu stranu; naznačen time da su nakupljeni materijali i sredstvo za stabilizaciju unaprijed utovareni u diskretne kapsule (8184) koje su umetnute u torpedo.
directing the carbonylation product stream to a second reaction zone where it is contacted with a catalyst, which catalyzes the conversion of beta propiolactone to acrylic acid; 
usmjeravanja struje produkta karboniliranja u drugo područje reakcije gdje dolazi u kontakt s katalizatorom, koji katalizira prevođenje B-propiolaktona u akrilnu kiselinu;
A280/560 absorption ratio 
A280/560 apsorpcijski omjer
The pharmaceutical composition of claim 13, wherein said CD19 x CD3 bispecific single chain antibody is MT103. 
Glukokoritkoid za uporabu u skladu s patentnim zahtjevom 9, pri čemu je navedeno CD19 x CD3 bispecifično jednolančano protutijelo MT103.
The first and second parts may be riveted or screwed to the inner part depending on e.g. the type of advertisement that is preferred. 
Prvi i drugi dio mogu biti zakovani ili učvršćeni vijcima na unutarnji dio, što ovisi o, na primjer, vrsti oglašavanja kakvo se želi.
A hydrate form of a salt according to any of the claims 1 to 6. 
Spoj, naznačen time, da je hidratni oblik soli u skladu sa zahtjevom 1.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
about 5% to about 40% by weight of progesterone; 
od 5 % do 40 % progesterona u odnosu na masu
A process as claimed in claim 2 wherein, a compound formula (VII), obtained in step (c), is treated with hydrochloric acid to get hydrochloric salt of compound formula (VII). 
Postupak iz patentnog zahtjeva 2, naznačen time, daje spoj formule (VII), dobiven u koraku (c), tretiran s klorovodičnom kiselinom kako bi se dobila klorovodična sol spoja formule (VII).
or a stereoisomer or a pharmaceutically acceptable salt thereof. 
ili njegov steroizomer ili njegova farmaceutski prihvatljiva sol.
An immunogenic composition according to clause 1 wherein said adjuvant composition further comprises a sterol, wherein the ratio of saponin: sterol is from 1:1 to 1:100 w/w. 
Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni adjuvantirani pripravak dodatno sadrži sterol, gdje se omjer saponin:sterol kreće od 1:1 do 1:100 tež./tež..
The liquid ring pump according to claim 1, wherein the outlet chamber is provided with a radial vane extending around a part of the drive shaft in the outlet chamber in the direction of the flow of sewage. 
Pumpa sa tekućim prstenom sukladno zahtjevu 1, naznačena time da je izlazna komora (17) snabdjevena radijalnom lopaticom (50), koja se pruža oko dijela pogonske osovine (16) u izlaznoj komori (17) u smjeru protoka otpadnih voda.
After stirring at room temperature for 1 hour, the resulting solution is treated with 4-nitrobenzyl bromide (1.0 g, 4.6 mmol) in one portion and stirring continues overnight. 
Nakon miješanja 1 sat pri sobnoj temperaturi, dobivenu otopinu se pomiješa sa 4-nitrobenzil bromidom (1,0 g, 4,6 mmola) u jednom obroku i miješanje se nastavi preko noći.
The method according to claim 1, wherein Service Information tables are transmitted on said pseudo-streams, said tables containing information necessary for knowing the frequency positions of the channels bonded together for transmitting said data stream and for identifying a master channel. 
Metoda prema jednom ili više od patentnih zahtjeva 1 do 8, gdje su tabele servisnih informacija, SI, prenesene na navedene pseudo-tokove (3c,3d), navedene tabele koje sadrže informacije neophodne za saznanje frekventnih pozicija kanala povezanih zajedno za prijenos navedenog toka (3) podataka i za identificiranje glavnog kanala.
The commercial package as claimed in Claim 12, wherein the rapamycin derivative is a compound of formula (III) wherein R1 is CH3 or C3-C6alkynyl; 
Komercijalno pakovanje u skladu sa zahtjevom 12, naznačeno time, da derivat rapamicina je spoj formule (III) [image] gdje je CH3 ili C3-C6alkinil;
Z is amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylcarbonylamino; 
Z je amino, supstituirani ili nesupstituirani alkilamino, supstituirani ili nesupstituirani dialkilamino, supstituirani ili nesupstituirani alkilkarbonilamino;
A pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound and at least one GLP-1 R (glucagon-like peptide-1 receptor) agonist for use in treating Type 2-diabetes in a patient, wherein the patient is a diet-treated Type 2-diabetic patient, a sulfonylurea-treated Type 2-diabetic patient, a far-advanced stage Type 2-diabetic patient and/or a long-term insulin-treated Type 2-diabetic patient. 
Farmaceutski pripravak koji sadržava barem jedan spoj FGF-21 (fibroblastni čimbenik rasta 21) i barem jedan agonist GLP-1R (receptora glukagonu sličnog peptida-1) agonist za uporabu za liječenje dijabetesa, naznačen time što farmaceutski pripravak nadalje sadrži prihvatljiv farmaceutski nosač, razrjeđivač ili pomoćnu tvar odabranu iz skupine koja se sastoji od sterilne vode, otopine soli koja sadrži oko 0.9% mg/ml benzil alkohola, Hankovu otopinu, Ringerov laktat, laktozu, dekstrozu, saharozu, trehalozu, sorbitol, i manitol.
a compound of Formula 1: or a pharmaceutically acceptable salt thereof, wherein: 
R'-O | (b, ili njena farmaceutski prihvatljiva sol, pri čemu:
ii) is capable of binding (auto)antibodies against the second extracellular loop (ECII) of B1-AR; and/or iii) is capable of inhibiting the interaction between B1-AR and (auto)antibodies against ECII of B1-AR. 
ii) se može vezati na (auto)protutijela protiv druge izvanstanične omče (ECII) B1-AR; i/ili iii) može inhibirati međudjelovanje između B1-AR i (auto)protutijela protiv ECII B1-AR.
In some embodiments, the method comprises administering to the subject a composition of the invention comprising a MASP-3 and optionally a MASP-2 inhibitor and further administering to the subject a terminal complement inhibitor that inhibits cleavage of complement protein C5. In some embodiments, the terminal complement inhibitor is a humanized anti-C5 antibody or antigen-binding fragment thereof. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što pripravak dodatno sadrži najmanje jedno od: sredstva za inhibiranje MASP-I, sredstva za inhibiranje MASP-2, kombinaciju sredstva za inhibiranje MASP-I i sredstva za inhibiranje MASP-2, i/ili inhibitor terminalnog komplementa koji inhibira cijepanje komplementnog proteina C5.
A gabapentin chemical composition under tablet or capsule form containing a granulate according to claim 12. 
Kemijska smjesa gabapentina u obliku tablete ili kapsule, naznačena time što sadrži granulat prema zahtjevu 12. t>&
for the drawing, the hospital data management system provides an operator with a coded (for example bar-coded) request; 
A2) kod vađenja, sustav za vođenje podataka bolnice snabdijeva operatora s kodiranim zahtjevom (na primjcr, s barkodom);
The aqueous formulation of item 7 comprising 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 2, naznačena time što sadrži 0,1 ug do 10 ug liksisenatida po jedinici inzulin glargina.
Adding at least one organic acid to the growth medium. Method according to claim 1, wherein the promotor comprises one or more of the following bp: 
dodavanje barem jedne organske kiseline u medij rasta radi iniciranja transkripcije sekvence za kodiranje proteina.
The crystalline form of Febuxostat, designated Form F10, according to claim 1, characterized by an X-ray powder diffraction pattern having peaks at 6.7°, 7.7°, 12.8°, 13.3° and 20.0° ± 0.2° 2θ. 
Kristalni oblik febuksostata, označen kao Oblik F10, u skladu s patentnim zahtjevom 1, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu, sa signalima na 6,7", 7,7%, 12,8%, 13,3% 1 20,0% +
an antisense oligomer which has a nucleotide sequence having at least 90% identity with a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene. 
antisensni oligomer koji ima nukleotidnu sekvencu koja ima najmanje 90% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 i ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.